CORCYM
16.7.2021 09:02:12 CEST | Business Wire | Press release
CORCYM, the new, independent, medical device company dedicated to providing patients and cardiac surgeons with the best solutions to fight structural heart disease, announces today the enrollment of the first patient in the MANTRA study. MANTRA (M itral, A ortic aN d T ricuspid post-maR ket S tudy in a reA l-world setting) is a prospective, multi-arm, multi-center, global, post-market clinical follow-up study that monitors the safety and performance of the complete CORCYM portfolio in a real-world setting.
“The MANTRA study has been designed leveraging the umbrella study concept, as it contains a master protocol with endpoints applicable across the treatment options together with additional sub-studies for specific devices and dedicated endpoints. MANTRA currently contains three sub-studies: an aortic study, a mitral and tricuspid study, and a third study fully dedicated to the Memo 4D annuloplasty ring,” explained Prof. Bart Meuris (University Hospital Leuven, Belgium) Coordinating Investigator of the MANTRA aortic sub-study and part of the MANTRA Steering Committee together with Prof. Serdar Günaydın (Ankara City Hospital, Turkey), Prof. Jörg Kempfert (Deutsches Herzzentrum Berlin, Germany) and Prof. Patrizio Lancellotti (University Hospital Liège, CHU Sart Tilman, Belgium).
The first patient was implanted in Italy, at Città di Lecce Hospital with a Bicarbon aortic mechanical valve, which has been CE mark approved for use with low-dose anticoagulant therapy in low-risk patients1 . Conducted worldwide, the MANTRA study is planned to enroll 1,750 patients in approximately 100 centers with follow-up to 10 years.
“We are glad to take part in the MANTRA study and to have started enrolling patients in its aortic sub-study. As a primary endpoint, we will verify the device success at 30 days as defined by the VARC guidelines2 . Study patients will be followed-up annually to 10 years to assess the device safety and performance, together with the patient quality of life,” reported Dr. Giuseppe Santarpino , Principal Investigator at Città di Lecce Hospital, Italy.
“The launch of the MANTRA study confirms CORCYM’s commitment to continuously generate new clinical evidence in collaboration with cardiac surgeons to help them treat patients better today and in the future,” commented Christian Mazzi , CORCYM CEO.
About CORCYM
CORCYM is a global, independent, medical device company entirely focused on state-of-the-art surgical solutions to fight structural heart disease. CORCYM has a presence in more than 100 countries with approximately 850 employees and ensures strong continuous support to patients, healthcare professionals and healthcare systems worldwide. For more information, please visit www.corcym.com
___________________________
References:
- INR range 1.5-2.5 in patients at low risk for thromboembolic events undergoing single mechanical aortic valve replacement, as demonstrated by Torella et al., Am Heart J; 160:171-8, 2010.
- VARC: Valve Academic Research Consortium (Généreux, et al. 2021 Eur Heart J, 42(19):1825-1857).
View source version on businesswire.com: https://www.businesswire.com/news/home/20210716005014/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
VELOCIFERO Takes Action Against Counterfeiting in China13.11.2026 17:32:00 CET | Press release
White s.r.o., exclusive owner of the VELOCIFERO brand, takes action in China to protect its intellectual property rights. Initial measures in Chongqing and Taizhou have already resulted in the seizure of vehicles alleged to be counterfeit. VELOCIFERO is taking action against counterfeiting in China. White s.r.o., the exclusive owner of the VELOCIFERO brand and its related intellectual property rights, has launched decisive measures to protect its creative and industrial assets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261113797570/en/ Photo courtesy of White s.r.o. “Vehicle sealed in Chongqing as part of actions undertaken to protect VELOCIFERO’s intellectual property rights.” The matter originated in June 2026 when, according to the company’s complaint, computers were removed from the technical office of Taizhou Siweiluo, the company appointed to manufacture VELOCIFERO products. White s.r.o. subsequently became aware
LangChain Raises $300M to Enable Every Company to Own Their Intelligence13.11.2026 16:53:00 CET | Press release
CapitalG leads Series C funding round at a $3B valuation to advance LangChain's agent engineering platform LangChain today announced it has raised $300 million in new funding at a $3 billion valuation, bringing total funding to date to $460 million. The round was led by existing investor CapitalG, with significant participation from new investors GIC and DFJ Growth and existing investors IVP and Sapphire Ventures. LangChain is advancing its mission to help every company own its intelligence. As agents transform the economy, companies are building domain-specific agents differentiated by their knowledge, data, and user experience. These agents will power new products and transform internal company operations, creating lasting competitive advantages for the companies that control them. "Agents are going to transform how companies operate and the products they deliver. The companies that control these systems will build lasting competitive advantages," said Harrison Chase, Co-Founder and
Kinaxis Named a Leader in Five 2026 IDC MarketScapes for Worldwide Supply Chain Planning13.11.2026 13:00:00 CET | Press release
Maestro delivers concurrent planning on a single platform across discrete, process, consumer packaged goods and life sciences Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain planning and orchestration, today announced it has been named a Leader in five 2026 IDC MarketScape vendor assessments for worldwide supply chain planning. The recognition spans the overall market and four industries - discrete industries, process industries, consumer packaged goods and life sciences industries - all served by a single platform, Kinaxis Maestro®, the company's AI-powered supply chain orchestration platform. "Supply chain leaders don't need a better forecast once a month. They need to know what changed this morning, what it means across the business, and what to do about it," said Andrew Bell, Chief Product Officer of Kinaxis. "I believe being named a Leader across five IDC MarketScape vendor assessments, in industries that plan in very different ways, shows that a single concurr
SBC Medical Announces Capital and Business Alliance with NeuroBrain Dynamics to Advance Clinic Profitability Through Medical AI13.11.2026 12:30:00 CET | Press release
Companies to co-develop six medical AI solutions targeting revenue expansion and cost reduction; SBC Medical secures priority sales rights in Japan and South Korea and targets B2B expansion across Asia SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“The Company” or “SBC Medical”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields, today announced a strategic capital and business alliance agreement with NeuroBrain Dynamics Inc. (“NBD”), a Taipei-based company dedicated to enterprise generative AI solutions. As part of the agreement executed on November 13, 2026, SBC Medical has made a minority equity investment in NBD. Through this alliance, SBC Medical plans to introduce two complementary suites of generative AI solutions across its network of 287 clinics in Japan and overseas*: “revenue-growth AI,” to elevate average revenue per visit and customer retention through personalized customer guidance, and “cost-reduction AI,
SBC Medical Group Holdings Reports Third Quarter 2026 Financial Results13.11.2026 12:30:00 CET | Press release
Revenue Up 35%, Net Income Attributable to SBC Medical Up 22%, and Adjusted EBITDA1 Up 66% Year-over-Year; Net Income Margin of 27% and Adjusted EBITDA Margin of 47% — Previously Announced Service Fee Revisions and New Clinic Openings Contribute to Revenue Growth and Operating Margin Improvement SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Medical Services Organization (MSO) providing management support across a wide range of healthcare fields to medical institutions in Japan and abroad, today announced its consolidated financial results for the third quarter of fiscal year 2026 (the three months ended September 30, 2026) and the three cumulative quarters of fiscal year 2026 (the nine months ended September 30, 2026). Third Quarter 2026 Financial Highlights Total revenues were $59 million, up 35% year-over-year. Income from operations was $26 million, up 66% year-over-year, with an operating margin of 45%. Net income attributable to SBC Medi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom